NTLA
Intellia Therapeutics, Inc.
Nasdaq: NTLA · Cambridge, MA
$11.21+0.05 (+0.45%)Closed
Market Cap$1.57B
Cash$437.8Mmost recent
Runway11 mo$117.3M Q burn
P/E (TTM)—EPS $-3.81
52-Wk Range$8.04 – $25.60
Avg Volume5.6M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$11.21-29.3%
Pipeline
Drug candidates sponsored by Intellia Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | NTLA-2002 | Hereditary Angioedema | Active, not recruiting | 2026-02-10past | 1 | |
| Phase 3 | nexiguran ziclumeran | Neuromuscular Disease+19 more | Recruiting | 2027-07 | 1 | |
| Phase 3 | NTLA-2001 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy+3 more | Recruiting | 2027-12 | 2 | |
| Phase 1 | Arm 1: NTLA-5001 | Acute Myeloid Leukemia | Terminated | 2022-07-21past | 1 | |
| Phase 1 | Biological NTLA-2002 | Hereditary Angioedema | Active, not recruiting | 2024-04-04past | 1 | |
| Phase 1 | Biological NTLA-3001 | Lung Disease+4 more | Withdrawn | 2025-01-09past | 1 | |
| N/A | Unnamed | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy+2 more | Enrolling | 2038-03 | 1 | |
| N/A | Unnamed | Hereditary Angioedema | Enrolling | 2040-04 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Gene editing · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.